Showing 321 - 340 results of 35,235 for search '(( 50 ((a decrease) OR (((we decrease) OR (nn decrease)))) ) OR ( a fold decrease ))', query time: 0.86s Refine Results
  1. 321
  2. 322

    Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: A Double-Blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy by Yong-Chul Kim (1637572)

    Published 2013
    “…We randomly assigned patients either to receive tacrolimus or placebo with stratification by using a renin angiotensin system blocker. …”
  3. 323

    Neural networks classify states which differ in neuronal activity levels using ensembles of neurons that increase/decrease their activity in each state. by Nicholas A. Frost (10739821)

    Published 2021
    “…As a result, there is an increase (neurons 51:100) or decrease (neurons 1:50) in activity levels in State B compared to State A. …”
  4. 324
  5. 325

    The decrease of C/EBPα protein during apoptosis involves induction of protein degradation and inhibition of transcription. by Meng Zhao (54299)

    Published 2009
    “…Then, C/EBPα protein was detected with β-actin as a loading control. Folds of decrease of C/EBPα protein/β-actin ratios against untreated cells are shown as means±SD of three independent experiments. …”
  6. 326
  7. 327

    Structural Alterations of the “Address” Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG Toxicity by Hongguang Ma (5105198)

    Published 2023
    “…Follow-up hERG channel inhibition evaluation revealed a seven-fold decreased potency of compound <b>21</b> compared to NAN. …”
  8. 328
  9. 329
  10. 330

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  11. 331

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  12. 332

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  13. 333

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  14. 334

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  15. 335

    Response of small airway tissues infected with EV-D94 and decreasing doses of EV-D68. by Ines Cordeiro Filipe (5849144)

    Published 2022
    “…<p>Tissues were infected with 1E7 RNA copies of EV-D94 (equivalent to 2,46E4 TCID50) and 1E7 RNA copies of EV-D68 (3,3E5 TCID50) as well as decreasing doses of the latter. …”
  16. 336

    Different Association of Human Papillomavirus 16 Variants with Early and Late Presentation of Cervical Cancer by Ana Alfaro (280118)

    Published 2016
    “…Only the D2 variant conferred a 3.3-fold increase in the risk of developing CC before 50 years of age (OR = 3.3, 95% CI = 1.7–6.6, p < 0.001) in relation with non-HPV16 cases. …”
  17. 337
  18. 338
  19. 339
  20. 340